BKHA Black Hawk Acquisition Corp
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 2000775 · Fiscal year ends 11/30
Financial factors as of 2026-08-31 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-37.7%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA5.3%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets18.2%
Debt / equity—
Current ratio0.02x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-0.43x
Accruals ratio7.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-11-30 | FY20242024-11-30 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| SG&A expense | $795,510 | $492,131 |
| Operating income | -$915,510 | -$576,076 |
| Interest expense | $15,454 | — |
| Net income | $1.33M | $1.92M |
| EPS (diluted) | — | — |
| Banking | ||
| Net interest income | $2.26M | $2.48M |
| Deposits | $690,000 | $690,000 |
| Balance sheet | ||
| Cash & equivalents | $0 | $264,842 |
| Current assets | $50,790 | $314,071 |
| Intangibles | $5.00M | — |
| Total assets | $23.88M | $72.14M |
| Current liabilities | $1.48M | $70,978 |
| Total liabilities | $3.90M | $2.49M |
| Shareholders' equity | -$3.85M | -$2.17M |
| Cash flow statement | ||
| Operating cash flow | -$650,321 | -$553,665 |
| Investing cash flow | $50.26M | -$69.34M |
| Financing cash flow | -$49.84M | $70.04M |
· This company does not report gross profit in XBRL.
· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.